Format

Send to

Choose Destination
Oncotarget. 2019 Jan 11;10(4):551-557. doi: 10.18632/oncotarget.26560. eCollection 2019 Jan 11.

Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy.

Author information

1
Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA.
2
University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
3
Kaiser Permanente Southern California, Los Angeles, CA, USA.
4
Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
5
Department of Radiology and Imaging, Children's Hospital Los Angeles, Los Angeles, CA, USA.
#
Contributed equally

Abstract

Outcomes for children with high-grade gliomas (HGG) remain dismal despite aggressive treatment strategies. The use of targeted therapy for BRAFV600E mutated malignancies including HGG is being explored as a potentially well tolerated and effective therapeutic option. The results of adult melanoma studies demonstrating that combination therapy with BRAF inhibitors and MEK inhibitors results in prolonged survival led us to employ this treatment strategy in children with BRAFV600E mutated HGG. In this case series, we describe three pediatric patients with HGG with confirmed BRAFV600E mutation who demonstrated responses to combination therapy with dabrafenib and trametinib.

KEYWORDS:

BRAF mutation; high-grade glioma; pediatrics; targeted therapy

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center